| iPSC-Cardiomyocyte (iCM) Line | Genetic Mutation | Clinical Disease |
|---|---|---|
|
CB-iCM-MYBPC3e6-het (Mutant) |
Frame shift mutation in exon 6. | Hypertrophic Cardiomyopathy |
|
CB-iCM-MYBPC3e6-corr (Isogenic Control) |
CRISPR-corrected mutation. | – |
*Special pricing available for first-time orders. Inquire for academic and bulk discounts.
Hypertrophic Cardiomyopathy (HCM) is the most common genetic heart disease, affecting an estimated 1 in 500 individuals worldwide. Mutations in the MYBPC3 gene are the single most common cause of HCM*, accounting for up to 50% of all familial cases.
Accelerate your drug discovery and mechanistic studies for HCM with the MYBPC3e6 Isogenic Pair—the industry's first commercially available hypertrophic cardiomyopathy isogenic pair cell line. This validated model provides an unmatched platform to precisely study the disease phenotype and evaluate therapeutic candidates.
*Garcia-Hernandez et al., Can J Cardiol, 2024
This groundbreaking pair consists of an induced pluripotent stem cell (iPSC) line carrying a pathogenic mutation and its genetically CRISPR-corrected control.
The mutant line was generated from peripheral blood mononuclear cells of a male Caucasian patient diagnosed with hypertrophic cardiomyopathy. The isogenic control provides the critical, genetically matched wild-type reference to isolate and study the specific effects of the MYBPC3 mutation.
With the MYBPC3e6 Isogenic Pair, you gain:
Genetic Fidelity: An isogenic control created by CRISPR/Cas9 for high-confidence results.
Physiological Relevance: Functional validation using cutting-edge Engineered Heart Tissues (EHTs) and Curi Bio's proprietary platforms.
Translational Power: Phenotypes, including hypercontractility and impaired relaxation, that are clinically relevant and responsive to known therapeutics like Mavacamten.
